1.60Open1.60Pre Close0 Volume2 Open Interest22.50Strike Price0.00Turnover82.27%IV5.69%PremiumDec 20, 2024Expiry Date0.34Intrinsic Value100Multiplier5DDays to Expiry1.26Extrinsic Value100Contract SizeAmericanOptions Type-0.5397Delta0.1820Gamma21.10Leverage Ratio-0.0856Theta-0.0017Rho-11.39Eff Leverage0.0105Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet